ImmuPharma PLC announced that the ongoing 52-week, randomised, double-blinded, Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, is now complete, following the last patient having attended their final assessment. Final patient data from the trial are being collated and entered into the database, checked and analysed. This process is ongoing and top line results remain on track to be reported by the end of first quarter of 2018.